Summary: Concomitant administration of certain fluoroquinolone antimicrobials and nonsteroidal antiinflammatory agents (NSAIDs) induces serious convulsion in humans. There are differences in convulsive activity among fluoroquinolones and in the potentiation of fluoroquinolone-induced convulsion among NSAIDs, but a comprehensive, quantitative comparison has not been carried out. This study evaluates the inhibitory effects of twelve fluoroquinolones (ciprofloxacin, enoxacin, fleroxacin, gatifloxacin, levofloxacin, lomefloxacin, norfloxacin, ofloxacin, pazufloxacin, prulifloxacin, sparfloxacin, and tosufloxacin) alone or in the presence of an NSAID (4-biphenylacetic acid, diclofenac sodium, loxoprofen, lornoxicam or zaltoprofen) on the GABAA receptor binding of [ 3 H]muscimol in an in vitro study using mice synaptic plasma membrane. The rank order of inhibitory effects of the fluoroquinolones was prulifloxacin §norfloxacinÀciprofloxacinAEenoxacinÀgati-floxacinAEofloxacin §tosufloxacin §lomefloxacinÀlevofloxacinAEsparfloxacinAEpazufloxacin §fleroxacin. 4-Biphenylacetic acid most potently enhanced the inhibitory effects of the fluoroquinolones, while zaltoprofen, loxoprofen, lornoxicam and diclofenac had essentially no effect. The clinical risk of convulsion for each combination was estimated using a pharmacodynamic model based on receptor occupancy using the in vitro data set obtained and pharmacokinetic parameters in humans collected from the literature. The combinations of 4-biphenylacetic acid with prulifloxacin and enoxacin were concluded to be the most hazardous.
Introduction
Fluoroquinolone antimicrobial agents are widely used for the treatment of various infections, because of their broad spectrum of antimicrobial activity. 1) Central nervous system (CNS) reactions such as headache, dizziness, convulsion, insomnia and psychosis are clinically significant side effects of these agents, although their incidence is as low as 1-2%. 2) Severe CNS adverse reactions of fluoroquinolones include convulsions, and the incidence of convulsion increases when nonsteroidal antiinflammatory agents (NSAIDs) are used concomitantly with fluoroquinolones. 1) Fluoroquinolone-induced CNS excitation is attributable to the inhibition of g-aminobutyric acid (GABA) binding to the GABAA receptor. 3) Some NSAIDs such as fenbufen, potentiate the blockade of the GABAA receptor by fluoroquinolones, though fenbufen itself does not inhibit GABAA receptor binding at all. 4) Previous reports suggest that there are differences according to the fluoroquinolone in convulsive activity and differences among NSAIDs in the potentiation of fluoroquinolone-induced convulsions, 5) but comprehensive information is not yet available. We previously reported that the convulsive activity of at least some combinations of fluoroquinolones and NSAIDs is synergistic, as determined using isobolograms for the occurrence of convulsions and the concentrations of enoxacin (ENX) and three NSAIDs in mouse brain. 6) We have also shown that the convulsive activity of fluoroquinolones in vivo can be estimated from in vitro studies of receptor occupancy. 6, 7) This study investigates the convulsive activity of twelve fluoroquinolones in the presence or absence of five NSAIDs, using GABAA receptor binding assay. For fenbufen, we investigated the effect of its metabolite, 4-biphenylacetic acid (BPAA), which accounts for the potentiation of convulsive activity. 6) We also estimated the risk of convulsion in a clinical setting using a pharmacodynamic model based on receptor occupancy.
Methods
Materials: Pazufloxacin (PZFX) and tosufloxacin (TFLX) were kindly supplied by Mitsubishi Pharma Co., Ltd. (Tokyo, Japan) and Taisho Toyama Pharmaceutical Co., Ltd. (Tokyo, Japan), respectively. The active metabolite of prulifloxacin (PUFX), NM394, was supplied by Meiji Seika Kaisha, Ltd. (Tokyo, Japan). Enoxacin (ENX), ofloxacin (OFLX), lomefloxacin (LFLX) and norfloxacin (NFLX) were purchased from Sigma Chemical Co., Ltd. (St. Louis, MO, USA). Ciprofloxacin (CFLX), fleroxacin (FLRX), gatifloxacin (GFLX), levofloxacin (LVFX) and sparfloxacin (SPFX) were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Lornoxicam and zaltoprofen were kindly supplied by Taisho Toyama Pharmaceutical Co., Ltd. and Nippon Chemiphar Co., Ltd. (Tokyo, Japan), respectively. Loxoprofen, 4-biphenylacetic acid (BPAA; the active metabolite of fenbufen) and diclofenac sodium were purchased from Sigma Chemical Co., Ltd. and Wako Pure Chemical Industries, Ltd. [ 3 H]Muscimol (specific activity; 29.5 Ci/mmol), a specific GABAA receptor agonist, was purchased from Perkin Elmer Life Sciences, Inc. (Boston, MA, USA). All other reagents were commercial products of analytical grade.
Animals: The protocol for the animal study was approved by the Ethical Committee on Animal Experiments of the Faculty of Pharmaceutical Sciences, Kyushu University. Male ddY mice (18-20 g) were purchased from Seak Yoshitomi (Fukuoka, Japan) and kept under standard laboratory conditions (food and water ad libitum, room temperature 22±19 C and light on from 7:00 to 19:00) for at least 7 days before use.
Preparation of synaptic plasma membranes: Synaptic plasma membranes were prepared from the brains of ddY mice by the method of Enna et al., 8) with minor modification. Whole brains were homogenized in 10 volumes 0.32 M sucrose using a Teflon-on-glass tissue homogenizer (Mini D.C. stirrer, EYLA, Tokyo, Japan). The homogenate was centrifuged at 1,000×g for 10 min and the supernatant was centrifuged at 20,000×g for 20 min. The crude pellet was suspended in 50 volumes 50 mM Tris-HCl buffer (pH 7.4) using a sonicator (VibtraCell VCX400, Sonics and Materials, CT, USA) and centrifuged at 48,000×g for 20 min. The resultant pellet was suspended in 0.05% Triton X-100, incubated at 379 C for 20 min and washed three times in the buffer. All these processes were carried out at 49 C, except for 0.05% Triton X-100 treatment. The final suspension could be stored at -809 C for at least 90 days without loss of binding capacity. H]muscimol (10 nM) solution, 100 mL buffer or quinolone solution and 100 mL buffer or NSAIDs solution, was incubated at 49 C for 30 min. An aliquot of 800 mL of the preparation was filtered through a glass fiber filter (GF/C, Whatman Inc., Clifton, NJ, USA) and washed twice with 5 mL ice-cold buffer using a cell harvester (Millipore Intertech, MA, USA). The radioactivity of the filters was determined in 5 mL scintillation cocktail (Clearsol I, Nacalai Tesque, Kyoto, Japan), using a liquid scintillation counter (LC3500, Aloka Co. Ltd., Tokyo, Japan). Nonspecific binding was determined in the presence of 1 mM unlabled GABA and the results were expressed as specific [ H]muscimol binding to the GABAA receptor, the following model, previously developed by us, 6) was used with minor modification. With regard to the binding of fluoroquinolones and NSAIDs to GABAA receptor, three mass balance equations [1] [2] [3] may be written, as
where Ki? (mM) is the inhibitory constant of the fluoroquinolone for the NSAID-GABAA receptor complex, Kd (mM) is the dissociation constant of the NSAID for GABAA receptor and g is the Hill coefficient (number of NSAID molecules that interact with the GABAA receptor). We assumed that NSAID increases the binding affinity of fluoroquinolones (KiÀKi?). The receptor occupancy (F) of the fluoroquinolones is described by equation (4). (1)- (3) into equation (4) yields equation (5).
Then, specific binding of [ 3 H]muscimol (SB; percent of control) may be represented by equation (6) .
Equation (6) was simultaneously fitted to the inhibitory response curves of each fluoroquinolone in the presence and absence of an NSAID by a nonlinear least-squares regression using Marquardt-Levenberg iterative curve-fitting method (MLAB, Civilized Software, MD, USA) with constant weight to obtain Ki and Ki/Ki? for each combination of fluoroquinolone and NSAID and Kd g and g for each NSAID.
Estimation of unbound concentrations of drugs in the human brain: To quantitatively estimate the risk of convulsion in humans, we estimated the unbound concentrations of drugs in the human brain (Cbrain, f) with equation (7).
Cbrain, f ＝C ss (max) ･K p ･f T100 (7) where Css (max), Kp and fT100 represent the maximum plasma concentration of drug at the steady state after the standard dosage regimen, the ratio of AUCbrain to AUCplasma in rats or mice and the unbound fraction of each drug in the whole brain, respectively. First, the plasma concentration profile of each drug after single oral administration was obtained from the literature and 1-or 2-compartment open model with first order absorption was fitted to the profile by a nonlinear least-squares regression method 9) to obtain respective pharmacokinetic parameters. Css (max) was calculated from the paramenters. Kp of each drug in humans was assumed equal to that in rats or mice, as indicated in the literature. Kp was calculated as the ratio of AUCbrain to AUCplasma in rats or mice. The volume of brain capillary was assumed to be 0.008 mL/g tissue, unless otherwise stated in the literature and used to correct Kp. The unbound fraction of each drug in the whole brain (fT100) was also assumed equal to that in mice, measured by equilibrium dialysis and HPLC as previously described. 6) Prediction of GABAA receptor occupancy of fluoroquinolones in the human brain: Putative GABAA receptor occupancy (Fpred) of a fluoroquinolone in the human brain was estimated by substituting [Q] and [S] into equation (5) with Cbrain, f of the fluoroquinolone and NSAID, respectively, derived from equation (7).
Results
Inhibitory effects of fluoroquinolones and NSAIDs on [ Figure 2 . In general, PUFX, NFLX, ENX and CPFX show relatively larger Ki/Ki? than others irrespective of NSAIDs, implying these fluoroquinolones are susceptible to potentiation of convulsive activity by NSAIDs.
Prediction of GABAA receptor occupancies of fluoroquinolones in the human brain: Table 6 shows Cbrain, f of each drug obtained using Kp, fT100 and Css (max). Table 7 shows Fpred of fluoroquinolones in the absence or presence of NSAIDs estimated using Cbrain, f The inhibitory effects of fluoroquinolones on [ 3 H]muscimol binding in the presence of BPAA was fitted to equation (6) , and pharmacodynamic parameters were obtained as described in``Materials and Method''. Each value represents the estimate±SD (n＝3). Ki is the inhibitory constant of fluoroquinolones for GABA A receptor, Ki? is the inhibitory constant of fluoroquinolones for NSAIDs-GABA A receptor complex, Kd g is the dissociation constant of NSAIDs for GABA A receptor and g is the number of NSAID molecules that interact with GABA A receptor. Kd g and g for BPAA were estimated as 2700± 2660 and 1.45±0.11, respectively. Further details as in Table 1 . Kd g and g for zaltoprofen were estimated as 438 ±888 and 0.959±0.151, respectively. Further details as in Table 1 . Kd g and g for diclofenac sodium were estimated as 534±610 and 1.31±6.11, respectively. ( Table 6 ) and pharmacodynamic parameters ( Tables  1-5) . Zaltoprofen, loxoprofen, lornoxicam and diclofenac sodium were considered unlikely to increase Fpred of fluoroquinolones.
Discussion
This study estimates the risk of convulsion in humans following concomitant administration of fluoroquinolones with or without NSAIDs on the basis of pharmacokinetic and pharmacodynamic analyses. The pharmacodynamic parameters for the binding of fluoroquinolones and NSAIDs were obtained by the in vitro study in mice, while their pharmacokinetic parameters in humans were taken from the literature. The present model-based approach enables us to estimate quantitatively the risk of convulsion of fluoroquinolones and potentiation by NSAIDs in humans from in vitro data and pharmacokinetic parameters. This approach becomes practical only when comprehensive in vitro data on the inhibitory effects of various fluoroquinolones in the presence of various NSAIDs are available and therefore, we measured a total of 240 inhibitory curves for combinations of the 12 fluoroquinolones and 5 NSAIDs (at 0, 1, 10 and 100 mM), to obtain comprehensive pharmacodynamic parameters.
A comparison of Fpred of individual fluoroquinolones in the presence of BPAA allowed us to assess the risk of convulsion. Briefly, the rank order of Fpred in the presence of BPAA was PUFXÀENXÀFLRX §NFLXAE CPFXÀLFLXAEOFLXAEPZFXÀLVFX §GFLXAESPFX AETFLX. Hori et al. have reported doses for convulsion (ED50) after intravenous administration of quinolones concomitantly with 5 nmol BPAA. 10) To simply correct them by clinical dose, since the ordinary dose in humans differs according to the fluoroquinolone, we calculated the ratio of ED50 and the ordinary daily dose of respective Unbound drug fraction in the whole brain (f T100 ) was determined by equilibrium dialysis and HPLC, using mouse brain homogenate.
d
Unbound drug concentration in the human brain (C brain, f ; mg/g brain) was estimated by applying the equation (7) reported the rank order of convulsion onset time (min) after intravenous administration of 25 mg/kg fluoroquinolones with 400 mg/kg BPAA to be ENX, NFLX, and LFLX, CPFXºOFLXº SPFX, TFLX.
Comparison of Fpred of fluoroquinolones alone or with NSAIDs revealed the potentiation effect of each NSAID on the convulsive activity of the fluoroquinolones. Zaltoprofen, loxoprofen, lornoxicam, and diclofenac sodium did not substantially affect Fpred of fluoroquinolones, suggesting that these four NSAIDs may not enhance the risk of convulsion in humans given usual dosage regimens. Among various NSAIDs, phenylacetic acid and propionic acid derivatives, such as fenbufen, flurbiprofen and ketoprofen, have been reported to potently enhance the convulsive activity of fluoroquinolones 10) and the inhibition of GABAA current by fluoroquinolones. 5) However, diclofenac, a phenylacetic acid-derived NSAIDs, as well as zaltoprofen and loxoprofen, propionic acid-derived NSAIDs, exhibited far weaker potention than BPAA in the present study (Fig. 2) . These results suggest that each NSAID has unique characteristics with regard to drug interaction with quinolones, even among NSAIDs classified in the same group. Oxicam derivates, such as tenoxicam and piroxicam, have been shown not to act as potentiators of the convulsive activity of fluoroquinolones, 10) in accordance with the present results for lornoxicam. However, except for the combination of PUFX and BPAA, Fpred were only less than 1%, this being inconsistent with our previous report in mice showing that blockade up to 1-2% or more may be necessary to induce con-vulsion. 6) Since the absolute Fpred to exert convulsion is uncertain, the results of this study should be interpreted as relative, but not absolute risk.
For zaltoprofen and diclofenac, their potentiation of the inhibitory effects of NQs on [ 3 H]muscimol binding were considerable weak (Fig. 2) and Kd g obtained was considerably higher than the concentration range investigated in the in vitro study (1 to 100 mM), so that pharmacodynamic parameters such as Ki/Ki? could not be accurately obtained.
We estimated the risk of convulsion in humans using the binding parameters of drugs with mouse synaptic membranes. No significant differences were found between the binding characteristics of [ 35 S]TBPS to synaptic plasma membranes of human and rats, 11) suggesting that interspecies differences in the binding affinities may not be great. With regard to the distribution of drugs in the brain, we also used Kp and fT100 obtained in mice to estimate the risk of convulsion in humans (Table 6) , because the brain distribution of fluoroquinolones in rodents has been shown to be quite similar to that in humans. For example, Kp of FLRX in rats and humans are 0.31 (AUCbrain/AUCplasma) and 0.29 (AUCbrain/AUCblood), respectively. 12, 13) Similarly, to the best of our knowledge, no marked differences have been reported in Kp, brain of fluoroquinolones or NSAIDs between rats and mice. Plasma protein binding values of fluoroquinolones and NSAIDs in humans are 20-40% 14) and À97%, 15) respectively, and are similar to those in rodents. [16] [17] [18] [19] [20] [21] It is thus reasonable to assume that the binding characteristics of these drugs to brain tissue (fT100 values) in rodents are comparable to those in humans.
In conclusion, this study demonstrates that the risk of convulsion of twelve fluoroquinolones may be potentiated by the concomitant administration of a standard dosage of fenbufen, but not zaltoprofen, loxoprofen, diclofenac or lornoxicam. Our results indicate that comprehensive information on the convulsive activity of fluoroquinolones and its potentiation by NSAIDs can be obtained by in vitro studies and kinetic analysis based on a pharmacodynamic model.
